Previous 10 | Next 10 |
2024-05-03 17:20:20 ET More on FibroGen FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript FibroGen falls after early-stage data for prostate cancer drug AstraZeneca returns right to roxadustat...
2024-05-03 15:00:00 ET More on the markets My Current View Of The Market: May 2024 Edition (Technical Analysis) SPY: The 'Value' From Equities Is Historically Low SPY: The Setup Looks Extremely Bearish 'Sell in May and go away': Does it apply in 2024? ...
SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further det...
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been select...
2024-04-03 15:54:24 ET More on FibroGen FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript AstraZeneca returns right to roxadustat to FibroGen Seeking Alpha’s Quant Rating on FibroGen ...
2024-04-03 10:00:34 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Eli ...
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients: Median radiographic progression free survival of 8.7 months PSA50 response in 36% ...
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Ti...
2024-03-12 12:21:11 ET More on Mid-day movers & stocks. FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes Lexaria slips ...
2024-03-11 07:37:37 ET More on FibroGen AstraZeneca returns right to roxadustat to FibroGen Seeking Alpha’s Quant Rating on FibroGen Historical earnings data for FibroGen Read the full article on Seeking Alpha For further details see: Fibro...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...